| Name | Title | Contact Details |
|---|
Valkyrie Enterprises is a Virginia Beach, VA-based company in the Business Services sector.
Commerce2America is a Miami, FL-based company in the Business Services sector.
Grand Printing is a Mundelein, IL-based company in the Business Services sector.
BH Cosmetics is a cutting-edge leader in color cosmetics based in Los Angeles, with omni-channel distribution on our direct-to-consumer e-commerce sites and across key retailers such as ULTA, dm and Beauty Bay. What were about? High-quality, enticing products at affordable prices. Because we believe ALL makeup lovers should be able to express themselves with stunning looks. And all of our products - including our beloved shadow palettes, brush sets and so much more - are 100% cruelty-free: always have been and always will be. Another plus? Over 90% of our catalog is vegan, with more extra-clean and sustainable options being created all the time. Our 70+ employees across the U.S. and Europe live by the motto "Be Heard, Be Curious, Be Seen" and aim to make a positive societal impact on our 1 million+ loyal customer base and 4 million+ global social community. Follow us on: Instagram: http://instagram.com/bhcosmetics Twitter: https://twitter.com/#!/bhcosmetics Facebook: http://www.facebook.com/bhcosmetics YouTube: http://www.youtube.com/user/BHCosmetics
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.